Atavistik Bio to present the discovery and characterization of novel allosteric JAK2 V617F selective inhibitors that suppress mutant-dependent signaling and proliferation while sparing wild-type ...
Eilean Therapeutics announced the advancement of ZE74-0282 into first-in-human clinical development. ZE74-0282 is a novel, highly selective inhibitor of the mutated Janus kinase 2 (JAK2) V617F variant ...
Brain Network Disorders review highlights role of JAK2 pathway in worsening ischemic stroke outcomes
Ischemic stroke is a major cause of death and disability, caused by a sudden loss of oxygen supply to the brain due to blocked blood vessels. Recanalization treatments such as intravenous thrombolysis ...
Eilean Therapeutics LLC has presented data for ZE74-0282, a novel small molecule that targets the JAK2 JH2 domain harboring the V617F mutation with no impact on wild-type JAK2.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback